Related content

Greater first year effectiveness drives favorable cost-effectiveness of brand risedronate versus generic or brand alendronate: modeled Canadian analysis

By Grima D.   Papaioannou A.   Thompson M.   Pasquale M.   Adachi J.  

Osteoporosis International, Vol. 19, Iss. 5, 2008-05 ,pp. : 687-697

Springer Publishing Company

Access to resources Recommend Favorite

High incidence of vertebral and non-vertebral fractures in the OSTRA cohort study: a 5-year follow-up study in postmenopausal women with rheumatoid arthritis

By Vis M.   Haavardsholm E.   Bøyesen P.   Haugeberg G.   Uhlig T.   Hoff M.   Woolf A.   Dijkmans B.   Lems W.   Kvien T.  

Osteoporosis International, Vol. 22, Iss. 9, 2011-09 ,pp. : 2413-2419

Springer Publishing Company

Access to resources Recommend Favorite

Targeted intervention reduces refracture rates in patients with incident non-vertebral osteoporotic fractures: a 4-year prospective controlled study

By Lih A.   Nandapalan H.   Kim M.   Yap C.   Lee P.   Ganda K.   Seibel M.  

Osteoporosis International, Vol. 22, Iss. 3, 2011-03 ,pp. : 849-858

Springer Publishing Company

Access to resources Recommend Favorite

Anemia and the risk of non-vertebral fractures: the Tromsø Study

By Jørgensen L.   Skjelbakken T.   Løchen M.-L.   Ahmed L.   Bjørnerem Å.   Joakimsen R.   Jacobsen B.  

Osteoporosis International, Vol. 21, Iss. 10, 2010-10 ,pp. : 1761-1768

Springer Publishing Company

Access to resources Recommend Favorite

Comparison of direct health care costs related to the pharmacological treatment of osteoporosis and to the management of osteoporotic fractures among compliant and noncompliant users of alendronate and risedronate: a population-based study

By Blouin J.   Dragomir A.   Fredette M.   Ste-Marie L.-G.   Fernandes J.   Perreault S.  

Osteoporosis International, Vol. 20, Iss. 9, 2009-09 ,pp. : 1571-1581

Springer Publishing Company

Access to resources Recommend Favorite